# RBM42

## Overview
RBM42 is a gene that encodes the RNA binding motif protein 42, a key player in RNA processing and regulation. The protein is characterized by its RNA recognition motif (RRM), which facilitates its binding to RNA and involvement in critical cellular processes such as splicing and translation. As an RNA-binding protein, RBM42 is integral to the modulation of gene expression, particularly in response to DNA damage, where it influences the splicing of genes like CDKN1A, which encodes the cell cycle regulator p21. This protein's interactions with various components of the spliceosome and translation machinery underscore its role in maintaining genomic stability and proper cellular function. RBM42's involvement in these processes highlights its potential significance in disease pathogenesis, including cancer and stress responses (BenOz2023A).

## Structure
RBM42 is a protein consisting of 480 amino acids and features an RNA recognition motif (RRM) at its C-terminal region. This RRM domain is crucial for its function in RNA binding and includes two main sequences: ribonucleoprotein 1 (RNP 1), an octapeptide sequence with eight conserved aromatic and positively charged amino acids, and ribonucleoprotein 2 (RNP 2), which contains six conserved amino acids (BenOz2023A). The RRM domain facilitates RBM42's interaction with RNA, playing a significant role in modulating splicing and translation processes, particularly during the DNA damage response (BenOz2023A).

The protein's structure allows it to interact with various components of the spliceosome and translation machinery, indicating its involvement in broader cellular pathways related to mRNA metabolism (BenOz2023A). While specific details about the secondary, tertiary, and quaternary structures of RBM42 are not provided, its functional domains and interactions suggest a complex structure capable of binding RNA and other proteins involved in splicing and translation regulation. The study does not mention any post-translational modifications or splice variant isoforms for RBM42.

## Function
RBM42 (RNA binding motif protein 42) is a crucial regulator of RNA processing, particularly involved in the splicing and translation of specific target genes. In healthy human cells, RBM42 plays a significant role in modulating the splicing of the CDKN1A gene, which encodes the p21 protein, a key regulator of cell cycle arrest during DNA damage response (BenOz2023A). RBM42 binds directly to CDKN1A RNA, promoting its splicing by counteracting the negative effects of the splicing regulator RBM4 (BenOz2023A). This interaction is essential for maintaining proper levels of p21, which ensures accurate DNA repair and cell cycle regulation (BenOz2023A).

RBM42 is also involved in the translation process, interacting with various translational factors and binding to 5'UTR regions of target transcripts. This suggests a coupling between splicing and translation machineries mediated by RBM42, which is crucial for fine-tuning gene expression (BenOz2023A). The protein is active in the nucleus, where it participates in post-transcriptional modification of RNA, impacting cellular growth and differentiation. Its role in these molecular processes highlights its importance in maintaining genomic stability and proper cellular function (BenOz2023A).

## Clinical Significance
RBM42 has been implicated in various diseases due to its role in RNA processing and regulation. In pituitary tumors derived from POU1F1 and NR5A1 cell lineages, RBM42 is up-regulated at both mRNA and protein levels, suggesting its involvement in the pathogenesis of these tumors. The up-regulation of splicing-related genes like RBM42 may contribute to the categorization of pituitary tumors based on their cell lineages and highlight the importance of spliceosome components in tumorigenesis (TaniguchiPonciano2020Proteomic).

In breast cancer, RBM42 is up-regulated in MCF-7 cells upon Taxol treatment, indicating its potential involvement in the splicing regulation of the ABCA7 gene. This suggests that RBM42 may play a role in the cellular response to chemotherapy and could be a factor in the development of drug resistance (Zappe2023Aberrant).

RBM42 is also associated with the regulation of miRNA packaging and release in response to thermal stress in bovine ovaries, indicating its broader role in stress responses and potential implications in reproductive health (Gad2023Extracellular). However, specific clinical significance of RBM42 gene mutations or expression alterations is not directly addressed in the available literature.

## Interactions
RBM42 (RNA binding motif protein 42) is involved in various interactions with proteins and nucleic acids, playing a significant role in RNA processing and regulation during the DNA damage response. It directly binds to CDKN1A RNA through its RNA recognition motif (RRM) domain, influencing the splicing and translation of the CDKN1A gene, which encodes the p21 protein (BenOz2023A). RBM42 interacts with several proteins involved in RNA processing, including RBM4, CUGBP1, LSM4, C8orff33, and hnRNP K (BenOz2023A). 

RBM42 counteracts the activity of RBM4, a splicing inhibitor, by modulating the splicing of CDKN1A. This interaction is crucial for regulating CDKN1A splicing, particularly following DNA damage, where RBM42 reduces RBM4's binding to CDKN1A RNA (BenOz2023A). RBM42 also interacts with CUGBP1, affecting CDKN1A translation. This interaction is modulated by DNA damage, with RBM42 enhancing its binding to CDKN1A RNA while suppressing CUGBP1 binding (BenOz2023A). 

RBM42's role extends to the translation of additional splicing targets, interacting with translational factors such as eIF2a, which is involved in initiating CDKN1A translation under stress conditions (BenOz2023A).


## References


[1. (BenOz2023A) Bella M. Ben-Oz, Feras E. Machour, Marian Nicola, Amir Argoetti, Galia Polyak, Rawad Hanna, Oded Kleifeld, Yael Mandel-Gutfreund, and Nabieh Ayoub. A dual role of rbm42 in modulating splicing and translation of cdkn1a/p21 during dna damage response. Nature Communications, November 2023. URL: http://dx.doi.org/10.1038/s41467-023-43495-6, doi:10.1038/s41467-023-43495-6. This article has 3 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-43495-6)

[2. (Gad2023Extracellular) Ahmed Gad, Kamryn Joyce, Nico Graham Menjivar, Daniella Heredia, Camila Santos Rojas, Dawit Tesfaye, and Angela Gonella-Diaza. Extracellular vesicle-micrornas mediated response of bovine ovaries to seasonal environmental changes. Journal of Ovarian Research, May 2023. URL: http://dx.doi.org/10.1186/s13048-023-01181-7, doi:10.1186/s13048-023-01181-7. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13048-023-01181-7)

[3. (TaniguchiPonciano2020Proteomic) Keiko Taniguchi-Ponciano, Eduardo Peña-Martínez, Gloria Silva-Román, Sandra Vela-Patiño, Ana Laura Guzman-Ortiz, Hector Quezada, Erick Gomez-Apo, Laura Chavez-Macias, Sophia Mercado-Medrez, Guadalupe Vargas-Ortega, Ana Laura Espinosa-de-los-Monteros, Baldomero Gonzales-Virla, Aldo Ferreira-Hermosillo, Etual Espinosa-Cardenas, Claudia Ramirez-Renteria, Ernesto Sosa, Blas Lopez-Felix, Gerardo Guinto, Daniel Marrero-Rodríguez, and Moises Mercado. Proteomic and transcriptomic analysis identify spliceosome as a significant component of the molecular machinery in the pituitary tumors derived from pou1f1- and nr5a1-cell lineages. Genes, 11(12):1422, November 2020. URL: http://dx.doi.org/10.3390/genes11121422, doi:10.3390/genes11121422. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes11121422)

[4. (Zappe2023Aberrant) Katja Zappe, Antonio Kopic, Alexandra Scheichel, Ann-Katrin Schier, Lukas Emanuel Schmidt, Yasmin Borutzki, Heidi Miedl, Martin Schreiber, Theresa Mendrina, Christine Pirker, Georg Pfeiler, Stefan Hacker, Werner Haslik, Dietmar Pils, Andrea Bileck, Christopher Gerner, Samuel Meier-Menches, Petra Heffeter, and Margit Cichna-Markl. Aberrant dna methylation, expression, and occurrence of transcript variants of the abc transporter abca7 in breast cancer. Cells, 12(11):1462, May 2023. URL: http://dx.doi.org/10.3390/cells12111462, doi:10.3390/cells12111462. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12111462)